Kynam Capital Management, LP
Long book
$1.58B
Q1 2026
Positions
36
Top-10 weight
72%
concentration
Last quarter
+15.7%
SPY +14.8%
Turnover
18%
of book per quarter
Strategy in plain words
auto-generated from filingsKynam Capital Management, LP is a concentrated fundamental stock-picker, specialised in healthcare (88% of the long book), running a $1.58B US long book across 36 positions.
The portfolio is concentrated: the top 10 names carry 72% of the portfolio. Turnover is modest: positions are typically held for years. Current anchor positions: SYNDAX PHARMACEUTICALS INC, CELLDEX THERAPEUTICS INC, VAXCYTE INC, COGENT BIOSCIENCES INC, VERA THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 5.9pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+0.6%
Q2 2024
+17.0%
Q3 2024
-5.7%
Q4 2024
-22.4%
Q1 2025
+1.0%
Q2 2025
+35.9%
Q3 2025
+46.1%
Q4 2025
+5.6%
Q1 2026
+15.7%
Sector allocation
Healthcare 82%
Materials 12%
Other 6%
Long book by quarter
What does Kynam Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 8.1M | $188.1M | 11.9% | Held |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 5.8M | $185.3M | 11.8% | -1.7% |
| PCVX VAXCYTE INC | Healthcare | 2.9M | $169.8M | 10.8% | Held |
| COGT COGENT BIOSCIENCES INC | Healthcare | 4.0M | $155.4M | 9.9% | -34.5% |
| VERA VERA THERAPEUTICS INC | Healthcare | 3.4M | $136.7M | 8.7% | -1.0% |
| BEAM BEAM THERAPEUTICS INC | Healthcare | 3.7M | $87.7M | 5.6% | +50.9% |
| CTMX CYTOMX THERAPEUTICS INC | Healthcare | 15.0M | $70.6M | 4.5% | +67.4% |
| BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 5.7M | $54.1M | 3.4% | -39.4% |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.6M | $46.6M | 3.0% | +203.0% |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 2.3M | $45.8M | 2.9% | +59.2% |
| CGEM CULLINAN THERAPEUTICS INC | Healthcare | 3.1M | $44.3M | 2.8% | Held |
| URGN UROGEN PHARMA LTD | Healthcare | 2.2M | $40.4M | 2.6% | New |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 1.8M | $36.7M | 2.3% | +0.6% |
| APLSUSD APELLIS PHARMACEUTICALS INC | — | 825.0K | $33.2M | 2.1% | -9.2% |
| MBX MBX BIOSCIENCES INC | Healthcare | 934.8K | $27.9M | 1.8% | Held |
| STRO SUTRO BIOPHARMA INC | Healthcare | 872.6K | $21.7M | 1.4% | +81.9% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 560.0K | $18.7M | 1.2% | New |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 1.2M | $18.5M | 1.2% | -39.4% |
| PHVS PHARVARIS NV | Healthcare | 640.4K | $18.1M | 1.1% | Held |
| EVMN EVOMMUNE INC | Healthcare | 625.5K | $14.4M | 0.9% | +237.2% |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 1.4M | $14.2M | 0.9% | Held |
| GERN GERON CORP | Healthcare | 6.8M | $10.2M | 0.6% | +97.8% |
| ENGN enGene Therapeutics Inc | Healthcare | 1.4M | $9.2M | 0.6% | -9.1% |
| DSGN DESIGN THERAPEUTICS INC | Healthcare | 784.6K | $8.3M | 0.5% | Held |
| WVE WAVE LIFE SCIENCES LTD | Healthcare | 965.2K | $7.0M | 0.4% | -55.5% |
| CLYM CLIMB BIO INC | Healthcare | 1.0M | $6.9M | 0.4% | -2.4% |
| BHVN BIOHAVEN LTD | Healthcare | 702.9K | $5.9M | 0.4% | Held |
| PRLD PRELUDE THERAPEUTICS INC | Healthcare | 1.6M | $5.4M | 0.3% | +101.9% |
| CRBU CARIBOU BIOSCIENCES INC | Healthcare | 2.5M | $4.8M | 0.3% | Held |
| ALEC ALECTOR INC | Healthcare | 2.0M | $4.3M | 0.3% | Held |
| PRQR PROQR THERAPEUTICS NV | Healthcare | 1.6M | $2.5M | 0.2% | Held |
| CADL CANDEL THERAPEUTICS INC | Healthcare | 200.0K | $980K | 0.1% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 39 | $1.62B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 37 | $1.57B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 35 | $1.34B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 31 | $928.8M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 32 | $1.19B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 30 | $1.69B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 25 | $1.30B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 26 | $1.30B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 23 | $955.5M | canonical | SEC ↗ |